inclusion criteria: * confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. * must have \>= 1 symptom associated with covid-19 with an onset of \<= 8 days prior to randomization. * hospitalized or plans for hospital admission due to covid-19 at the time of randomization or not currently hospitalized and does not have plans for hospital admission at the time of randomization, but is willing to be confined for ≥ 48 hours post-dose for the purposes of participating in this research study

inclusion criteria: * confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. * must have \>= 1 symptom associated with covid-19 with an onset of \<= 8 days prior to randomization. * hospitalized or plans for hospital admission due to covid-19 at the time of randomization or not currently hospitalized and does not have plans for hospital admission at the time of randomization, but is willing to be confined for ≥ 48 hours post-dose for the purposes of participating in this research study

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization or not currently hospitalized and does not have plans for hospital admission at the time of randomization, but is willing to be confined for ≥ 48 hours post-dose for the purposes of participating in this research study

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization or not currently hospitalized and does not have plans for hospital admission at the time of randomization, but is willing to be confined for ≥ 48 hours post-dose for the purposes of participating in this research study

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization and evidence of lower respiratory tract infection by clinical assessment or imaging. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization.

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid or antigen testing from respiratory swab, saliva, or other bodily fluid within 7 days prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization and evidence of lower respiratory tract infection by clinical assessment or imaging. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization.

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid testing from respiratory swab, saliva, or other bodily fluid within 72 hours prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization and evidence of lower respiratory tract infection by clinical assessment or imaging. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization.

inclusion criteria: - confirmed sars-cov-2 infection based on initial nucleic acid testing from respiratory swab, saliva, or other bodily fluid within 72 hours prior to randomization. - must have >= 1 symptom associated with covid-19 with an onset of <= 8 days prior to randomization and evidence of lower respiratory tract infection by clinical assessment or imaging. - hospitalized or plans for hospital admission due to covid-19 at the time of randomization.